Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients

Table 3 Response during and after therapy

Response	Ledipasvir-Sofosbuvir for 12 wk (n = 40), n (%)
HCV RNA < LLOQ1
During therapy period
At wk 4	34 (78.2)
At wk 12	40 (100)
After end of therapy
At wk 4	40 (100)
At wk 122	39 (97.5)
HCV viral breakthrough	0 (0)
HCV viral relapse	1 (2.5)
HIV viral breakthrough	7 (17.5)
HIV virologic rebound	2 (5)

¹LLOQ denotes lower limit of quantification (HCV RNA in serum, < 15 copies per milliliter HIV RNA in serum, < 40 copies per milliliter).

²A sustained virologic response 12 wk after the end of therapy was the primary end point. SVR: Sustained viral response.